Currently enrolling studies:
Dementia with Lewy Bodies Consortium
- The purpose of this study is to allow for the discovery of biomarkers and promote additional future research to improve the diagnosis, care and treatment in dementia with Lewy bodies.
- The consortium will collect detailed clinical information, biofluids, imaging data and ultimately autopsy results from individuals with dementia with Lewy bodies, mild cognitive impairment with a high likelihood of dementia with Lewy bodies, or Parkinson’s disease dementia. There will be annual visits for up to 5 years. A study partner/caregiver is required.
For further information about this and other studies, please contact Aishwarya Niraula by email firstname.lastname@example.org or phone 858-246-3190.
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (AscenD-LB)
- The main objective of this study is to evaluate the effectiveness of a study drug called Neflamapimod on cognitive function in patients diagnosed with Dementia with Lewy Bodies.
- People with dementia with Lewy bodies will use an oral medication for 21 weeks. The study will involve up to eight visits. Neurological examination and neuropsychological testing will be performed at each visit. A study partner/caregiver is required.